JPRN-jRCT1080222782未知Unknown
A Study to Evaluate the Effect of Azilsartan on Coronary Plaque in Essential Hypertensive Patients with Stable Angina and Dyslipidemia
TAKEDA PHARMACEUTICAL COMPANY LTD.0 个研究点目标入组 51 人开始时间: 2015年3月5日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 发起方
- 入组人数
- 51
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Patients with essential hypertension with office blood pressure before the start of study treatment (Week 0) meeting the following criteria who are appropriate for azilsartan therapy in the opinion of the principal investigator or investigator
- •- Patients aged >= 75 years at the time of informed consent: Sitting systolic blood pressure >= 150 mmHg or sitting diastolic blood pressure >= 90 mmHg
- •- Patients aged < 75 years at the time of informed consent who concurrently have type 2 diabetes mellitus: Sitting systolic blood pressure >= 130 mmHg or sitting diastolic blood pressure >= 80 mmHg
- •- Patients aged < 75 years at the time of informed consent who concurrently have chronic kidney disease (CKD) with proteinuria: Sitting systolic blood pressure >= 130 mmHg or sitting diastolic blood pressure >= 80 mmHg
- •- Patients meeting none of the above: Sitting systolic blood pressure >= 140 mmHg or sitting diastolic blood pressure >= 90 mmHg
- •2.Patients with stable angina with a coronary stenosis confirmed by coronary angiography who are planned to undergo percutaneous coronary intervention with stent placement (any type of stent)
- •3.Patients with findings of integrated backscatter intravascular ultrasound (IB-IVUS) to be performed before the start of study treatment (Week 0) showing plaque at >= 5 mm proximal to the proximal end of the inserted stent in the coronary artery
- •4.Patients with dyslipidemia meeting both of the following criteria:
- •- Patients treated with one HMG-CoA reductase inhibitor with no change in the dosage for at least 12 weeks before informed consent
- •- Patients with an LDL-C level of < 100 mg/dL as shown by a laboratory test performed within 4 weeks before informed consent
- •5.Men or women aged 20 or older at the time of informed consent
- •6.Patients capable of making outpatient study visits throughout the observation period
- •7.Patients who, in the opinion of the principal investigator or investigator, are capable of understanding the contents of the clinical study and complying with the study requirements
- •8.Patients capable of providing written consent in person before any study procedures
排除标准
- •1.Patients with secondary hypertension or malignant hypertension
- •2.Patients who took any renin-angiotensin system inhibitor within 12 weeks before informed consent
- •3.Patients who previously underwent coronary artery bypass grafting
- •4.Patients with type 1 diabetes mellitus
- •5.Patients with insulin therapy
- •6.Patients with an HbA1c level (National Glycohemoglobin Standardization Program [NGSP] value) of >= 7.0% as shown by a laboratory test performed within 4 weeks before informed consent
- •7.Patients with the plaque unevaluable because of severe calcification of the coronary artery shown by IB-IVUS to be performed before the start of study treatment (Week 0)
- •8.Patients with a change to their antidyslipidemic medication (including a change to the dosage) within 12 weeks before informed consent
- •9.Patients with clinically evident renal disorder (defined as eGFR < 30 mL/min/1.73m2)
- •10.Patients with severe liver disorder
- •11.Patients with hyperkalemia (defined as serum potassium >= 5.5 mEq/L)
- •12.Patients with a history of hypersensitivity or allergy to azilsartan
- •13.Patients participating in any other clinical study
- •14.Pregnant women, women with possible pregnancy, or breastfeeding women
- •15.Other patients who are inappropriate for participation in this study in the opinion of the principal investigator or investigator
研究者
相似试验
未知
Unknown
A study to explore the effects of Azilsartan compared to Telmisartan on insulin resistance of patients with essential hypertension on type 2 diabetes mellitus by HOMA-R (AT-HOMA)Essential hypertension complicated by type 2 diabetes mellitusJPRN-jRCT1080222411TAKEDA PHARMACEUTICAL COMPANY LTD.40
招募中
不适用
Evaluation for Efficacy and Safety of Azilsartan in Patients with HypertensioEssential HypertensionJPRN-UMIN000008577Department of Medicine and Bioregulatory SciencesThe University of Tokushima, Graduate School of Health Biosciences30
尚未招募
4 期
Effect of drug intervention on hypertensive patientsCTRI/2019/11/021961All India Institute of medical Sciences
已完成
不适用
Comparison of efficacy and safety of azilsartan and olmesartan in patients with essential hypertensioHypertensionJPRN-UMIN000016249Department of Cardiology, Fukuoka University School of Medicine60
已完成
不适用
Efficacy and safety of treatment with Azilsartan in type 2 diabetes mellitus patients with hypertension who did not show target blood pressure by telmisartan.Type 2 diabetes mellitus with hypertensionJPRN-UMIN000010604Iwasaki Naika Clinic20